Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study
2010

Mycophenolate Mofetil for Lupus Nephritis

Sample size: 33 publication Evidence: moderate

Author Information

Author(s): Laskari Katerina, Mavragani Clio P, Tzioufas Athanasios G, Moutsopoulos Haralampos M

Primary Institution: National and Kapodistrian University of Athens, Medical School

Hypothesis

The study aims to evaluate the efficacy and safety profile of mycophenolate mofetil (MMF) as maintenance therapy for proliferative lupus nephritis.

Conclusion

MMF appeared to be efficacious and safe as maintenance treatment for proliferative lupus nephritis.

Supporting Evidence

  • 73% of patients achieved renal remission by the end of follow-up.
  • 58% of patients achieved complete renal remission.
  • No patients developed chronic renal insufficiency or died during the study.
  • 58% of patients experienced non life-threatening drug adverse events.

Takeaway

This study shows that a medicine called mycophenolate mofetil can help people with a serious kidney problem caused by lupus, making them feel better and keeping them safe.

Methodology

Thirty-three patients received induction therapy with cyclophosphamide and steroids, followed by oral MMF as maintenance therapy for a median of 29 months.

Potential Biases

Potential bias due to the lack of a control group and the specific demographic of the cohort.

Limitations

The study is observational and lacks a randomized control group, and the cohort consisted mainly of Caucasian patients.

Participant Demographics

The cohort consisted of 33 patients, predominantly female (28 females, 5 males), with a median age of 30 years.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/ar3184

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication